Scholars@Duke

Treatment of lymphohistiocytic erythrophagocytosis with VP-16 and aziridinylbenzoquinone.

Publication ,  Journal Article
Becton, DL; Kurtzberg, J; Kinney, TR; Friedman, HS; Chaffee, S; Falletta, JM
Published in: Med Pediatr Oncol
1987
Published version (DOI) Link to item

Lymphohistiocytic erythrophagocytosis (LE) is a usually fatal disease characterized by fever, organomegaly, hyperlipidemia, central nervous system involvement, and cellular immunodeficiency. Treatment with corticosteroids, cytotoxic chemotherapy, and blood exchange is unsuccessful. We have treated two children with the epipodophyllotoxin VP-16 and with intrathecal chemotherapy. Each patient had an initial complete response, and one remains in remission 36 months after therapy began. Aziridinylbenzoquinone (AZQ) therapy induced a complete response in a patient who relapsed during VP-16 therapy. A combination of VP-16 and intrathecal chemotherapy appears to be the most effective therapy for LE, and further evaluation of the role of AZQ is indicated.

Duke Scholars

Joanne Kurtzberg
Author Joanne Kurtzberg Pediatrics, Transplant and Cellular Therapy
Henry Seth Friedman
Author Henry Seth Friedman Neurosurgery, Neuro-Oncology
John Matthew Falletta
Author John Matthew Falletta Pediatrics, Hematology-Oncology

Published In

Med Pediatr Oncol

DOI

10.1002/mpo.2950150203

ISSN

0098-1532

Publication Date

1987

Volume

15

Issue

2

Start / End Page

58 / 61

Location

United States

Related Subject Headings

  • Time Factors
  • Thiotepa
  • Remission Induction
  • Prednisone
  • Podophyllotoxin
  • Oncology & Carcinogenesis
  • Methotrexate
  • Male
  • Infant, Newborn
  • Hydrocortisone
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Becton, D. L., Kurtzberg, J., Kinney, T. R., Friedman, H. S., Chaffee, S., & Falletta, J. M. (1987). Treatment of lymphohistiocytic erythrophagocytosis with VP-16 and aziridinylbenzoquinone. Med Pediatr Oncol, 15(2), 58–61. https://doi.org/10.1002/mpo.2950150203
Becton, D. L., J. Kurtzberg, T. R. Kinney, H. S. Friedman, S. Chaffee, and J. M. Falletta. “Treatment of lymphohistiocytic erythrophagocytosis with VP-16 and aziridinylbenzoquinone.” Med Pediatr Oncol 15, no. 2 (1987): 58–61. https://doi.org/10.1002/mpo.2950150203.
Becton DL, Kurtzberg J, Kinney TR, Friedman HS, Chaffee S, Falletta JM. Treatment of lymphohistiocytic erythrophagocytosis with VP-16 and aziridinylbenzoquinone. Med Pediatr Oncol. 1987;15(2):58–61.
Becton, D. L., et al. “Treatment of lymphohistiocytic erythrophagocytosis with VP-16 and aziridinylbenzoquinone.” Med Pediatr Oncol, vol. 15, no. 2, 1987, pp. 58–61. Pubmed, doi:10.1002/mpo.2950150203.
Becton DL, Kurtzberg J, Kinney TR, Friedman HS, Chaffee S, Falletta JM. Treatment of lymphohistiocytic erythrophagocytosis with VP-16 and aziridinylbenzoquinone. Med Pediatr Oncol. 1987;15(2):58–61.

Published In

Med Pediatr Oncol

DOI

10.1002/mpo.2950150203

ISSN

0098-1532

Publication Date

1987

Volume

15

Issue

2

Start / End Page

58 / 61

Location

United States

Related Subject Headings

  • Time Factors
  • Thiotepa
  • Remission Induction
  • Prednisone
  • Podophyllotoxin
  • Oncology & Carcinogenesis
  • Methotrexate
  • Male
  • Infant, Newborn
  • Hydrocortisone